US-FDA-approves-vericiguat-for-patients-with-symptomatic-chronic-heart-failure

Vericiguat (Verquvo ® ) is the first soluble guanylate cyclase (sGC) stimulator to be approved for the treatment of symptomatic chronic heart failure / Vericiguat works on a pathway not currently targeted by existing heart failure treatments
Source: Bayer Company News - Category: Pharmaceuticals Source Type: news